Matthias Müllenbeck: What if we paid doctors to keep people healthy?
馬提亞斯.穆蘭貝克: 如果我們付錢給醫生,讓他們保持人民的健康,聽起來如何?
As the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology. Full bio
Double-click the English transcript below to play the video.
fell off the evening before.
I'm sitting in a dentist's chair.
so that I can get rid of my pain,
好讓我脫離牙痛之苦,
of a titanium implant surgery.
a damaged tooth
may add up to 10,000 US dollars.
可能會高達一萬美金。
that could be earned with me
還是能從我身上賺到的錢,
for my dentist?
wasn't an isolated case.
estimated that in the United States,
估計有三成──
surgical procedures --
and pacemaker implantations,
options had not been fully exploited
in other countries,
if you go to a doctor in the US,
to be subjected to a surgical intervention
會在不立即需要手術的情況下
an immediate need for it.
to run such unnecessary procedures?
去做這類不必要的手術?
health care systems themselves
certain procedures or treatments.
reimburse practitioners
對開業醫生的補助
of treatments performed,
數量和類型來給付,
that tempts some practitioners
誘使一些開業醫生
surgical treatments
other treatment options.
started to implement
health care systems' architecture
結構中,很少會有這種方式,
of a disease in the first place
applied to a patient
system's architecture --
of the incentive structure.
for keeping their customers healthy
once people are already sick.
已病之後的治療服務。
that largely cares for the sick,
people once they have become sick
從在大家生病之後才進行治療,
before they get sick.
就維持他們的健康。
of all those involved --
相關人士的焦點改變──
to pharmaceutical and medical companies --
及醫療器材公司──
ultimately sells:
最終要銷售的產品上:
reimburse practitioners
performed on a patient
individual is kept healthy
to an insurance company
is kept healthy
of acute medical intervention.
急性醫療干預就付款。
any further monetary compensation
所需要進行的醫療干預
to treat the disease of that individual,
for every evidence-based treatment option
讓客戶恢復健康的治療選擇,
will be paid again.
their customers healthy,
any unnecessary medical interventions
醫療干預,就能得到獎勵,
that eventually become sick.
to treat the sick will be,
for all parties being involved
structure shifts, now,
health care system
and singular treatment options,
且單一的治療選擇,
關注的是要做什麼
to stay healthy and live long.
to share their health data
understands early enough
就能在夠早的時間點
to their health is needed.
需要什麼樣的協助。
cardiometabolic profiling
and general practitioners,
and their physical activity --
身體活動相關的決策──
individual high-risk disease.
data analysis
of sensor technologies
of the individual health status possible.
個人健康狀況成為可能。
by devices like this
測量心血管代謝參數,
tumor DNA in your bloodstream
就先偵測你的血液中
for such monitoring technologies.
in certain oncological diseases
is diagnosed too late
that could potentially have cured them
been detected earlier.
based on a few milliliters of blood,
能根據幾毫升的血液
of circulating tumor DNA
detection can have
for non-small cell lung cancer
which is early, is 49 percent.
就診斷出來,五年存活率是 49%。
at stage four, which is late,
也就是很晚期才診斷出來,
to prevent a large number of deaths
血液循環腫瘤 DNA 的血液檢測,
for circulating tumor DNA
a manageable disease,
變成可以控管的疾病,
can likely be increased.
had a single chronic disease,
得了單一種慢性病,
of the $3 trillion US health care budget
健康照護預算有 86%
such chronic diseases.
to reduce this 86 percent,
not reacted and changed already?
還沒有反應和改變?
is a sick care system
that focuses on prevention
in the system to change.
每個行為者都做出改變。
to shift budgets and policies
and non-financial incentives.
和非財務獎勵方式。
a regulatory framework
of personal health data
stringent and sensible.
pharmaceutical and medical companies
藥廠,以及醫療器材公司
and, most important,
然後,最重要的是,
the willingness and motivation
in a sustained way,
生活方式,變得更永續,
the health data on a constant basis.
經常分享健康資料。
within the health care industry today
將獎勵的焦點改變為
more diseases in the first place
就先預防更多的疾病,
the onset of certain preventable diseases
可預防之疾病的發生,
and healthier lives for more people.
that we need to initiate that change
ABOUT THE SPEAKER
Matthias Müllenbeck - Business developerAs the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology.
Why you should listen
Throughout his career in various roles at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck worked on strategic asset, technology and diagnostic-licensing deals and on bringing to market innovative chemical products. He holds a PhD in immunology from the Humboldt University in Berlin and has worked at the Max-Planck Institute for infection biology in Berlin, at Bayer, and at the Albert-Schweizer Hospital in Lambarané, Gabon.
Matthias Müllenbeck | Speaker | TED.com